Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Spero Therapeutics's retained earnings for the quarter that ended in Dec. 2023 was $-391.07 Mil.
Spero Therapeutics's quarterly retained earnings
declined
from Jun. 2023 ($-439.06 Mil) to Sep. 2023 ($-442.26 Mil) but then
increased
from Sep. 2023 ($-442.26 Mil) to Dec. 2023 ($-391.07 Mil).
Spero Therapeutics's annual retained earnings
declined
from Dec. 2021 ($-367.46 Mil) to Dec. 2022 ($-413.88 Mil) but then
increased
from Dec. 2022 ($-413.88 Mil) to Dec. 2023 ($-391.07 Mil).
Spero Therapeutics Retained Earnings Calculation
Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.
Of course, if a company loses, it is called retained losses, or accumulated losses.
Spero Therapeutics (NAS:SPRO) Retained Earnings Explanation
Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.
For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.
If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.
Of course, many companies with negative retained earnings have indeed lost money in the past.
Retained Earnings: Warren Buffett's Secret.
One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.
If the company loses more than it has accumulated, retained earnings is negative.
If a company isn't adding to its retained earnings, it isn't growing its net worth.
Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.
Microsoft is negative because it chose to buyback stock and pay dividends.
The more earnings retained, the faster it grows and increases growth rate for future earnings.
Spero Therapeutics (Spero Therapeutics) Business Description
Traded in Other Exchanges
Address
675 Massachusetts Avenue, 14th Floor, Cambridge, MA, USA, 02139
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Executives
| Kamal Hamed |
officer: Chief Medical Officer |
675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE MA 02139 |
| Sath Shukla |
officer: Chief Financial Officer |
C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BUILDING #34, BOSTON MA 02129 |
| Timothy Keutzer |
officer: Chief Development Officer |
C/O SPERO THERAPEUTICS, INC., 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE MA 02139 |
| Ankit Mahadevia |
director, officer: See Remarks |
C/O SPERO THERAPEUTICS, INC., 675 MASSACHUSETTS AVE., 14TH FLOOR, CAMBRIDGE MA 02139 |
| Tamara L Joseph |
officer: Chief Legal Officer |
32 GARRISON STREET, APT 50-103, BOSTON MA 02116 |
| Aquilo Capital Management, Llc |
10 percent owner |
ONE LETTERMAN DRIVE, SUITE D4900, BUILDING D, SAN FRANCISCO CA 94129 |
| Kathleen Tregoning |
director |
C/O CEREVEL THERAPEUTICS HOLDINGS, INC., 131 DARTMOUTH STREET SUITE 502, BOSTON MA 02116 |
| Cristina Larkin |
officer: Chief Operating Officer |
C/O SPERO THERAPEUTICS, INC., 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE MA 02139 |
| Aquilo Capital, L.p. |
10 percent owner |
ONE LETTERMAN DRIVE, SUITE D4900, BUILDING D, THE PRESIDIO, SAN FRANCISCO CA 94129 |
| Scott Thomas Jackson |
director |
303B COLLEGE ROAD EAST, PRINCETON NJ 08540 |
| Stephen J. Dipalma |
officer: Interim CFO |
C/O SPERO THERAPEUTICS, INC., 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE MA 02139 |
| Cynthia Smith |
director |
508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019 |
| Pottage John C Jr |
director |
ACHILLION PHARMACEUTICALS, 300 GEORGE STREET, NEW HAVEN CT 06511 |
| Plc Glaxosmithkline |
10 percent owner |
980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS |
| Joel Sendek |
officer: Chief Financial Officer |
C/O SPERO THERAPEUTICS, INC., 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE MA 02139 |
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SPRO has been successfully added to your 